News | October 25, 2024
Piramal Pharma reports Q2 FY25 consolidated PAT at Rs. 22.59 Cr
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Piramal Pharma has reported total income of Rs. 2,302.86 crores during the period ended September 30, 2024
Solara Active Pharma Sciences has reported total income of Rs. 347.27 crores during the period ended September 30, 2024
JB’s absolute Scope1 & Scope2 emissions reduced by 13.9 % in the last financial year, despite turnover increasing by 11%
Clarity in regulatory frameworks and pathways help in preventing delays in accessing quality-assured, affordable medicines
The report highlights Piramal Pharma’s approach across four key strategic pillars: Responsible Operations, Business Resilience, Customer Centricity, and Quality & Excellence
Higher revenues backed by huge demand and expanding network contributed to the growth in bottom line
The company recorded sales of Rs. 1,129 crore for the fiscal year ended June 30, 2024,
India Business grew by 11.9% YoY to Rs. 1196.2 crore
Majority of organizations are looking to increase investments in public and hybrid cloud
European markets now contribute 51% of our business revenue up from 43% in Q4 FY24 and 34% in Q1 FY24
Subscribe To Our Newsletter & Stay Updated
